Effects of finasteride and bicalutamide on prostatic blood flow in the rat
FULL PDF: blackwell-synergy.com/doi/pd … 00.00671.x
Objective
To determine whether finasteride and bicalutamide, both currently used in the clinical management of patients with prostate diseases because they have antiandrogenic properties, have any effects on prostatic blood flow in a rat prostate model, as androgens are known to be involved in the regulation of prostatic blood flow and angiogenesis.
Materials and methods
Both finasteride and bicalutamide were supplied as oral suspensions in water and given daily to rats for 7 days by tube feeding. Blood flows to the ventral and dorsal prostates, and to the kidneys, were measured using the radioactive microsphere technique. In the bicalutamide experiments, some rats were treated with the Leydig cell toxin ethane dimethane sulphonate (EDS), to obtain a castration like effect, and one group of these rats received testosterone.
Results
Finasteride induced a clear decrease in blood flow to the ventral and dorsal prostates after 7 days of treatment, with no significant changes in blood pressure or kidney blood flow. Bicalutamide inhibited the testosterone induced increment of prostatic blood flow observed in EDS treated animals.
Conclusions
Finasteride, a blocker of 5αreductase, decreases prostate blood flow after 7 days of administration. The response was slower than that after castration, but was of similar magnitude. Blood flow was also decreased after treatment with the androgen receptor inhibitor bicalutamide. These observations suggest that prostatic blood flow is increased by dihydrotestosterone, and that the androgen receptor is responsible for mediating this effect.
From the PDF:
“… Finasteride has been shown to reduce prostatic bleeding in some patients with BPH… The mechanism behind this effect of finasteride on haematuria in patients with BPH is not fully known, but the present observation that prostatic blood flow can be markedly reduced by finasteride may be important.”